Interestingly, in contrast to the current study investigating patients with CRC in the metastatic setting, patients with nonmetastatic CRC with a KRAS A146–mutated tumor showed better survival compared with patients with mutations in other KRAS codons.4,54 Whereas the patients with early-stage CRC carrying a KRAS A146 mutation in the study of Janakiraman et al had more frequent KRAS copy-number gains, we did not observe such copy-number aberrations in the patients with KRAS A146 mutant mCRC. The gene discussed is KRAS; the disease is neoplasm.